Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Mark YatesAmanda MootooMaryam AdasKatie BechmanSanketh RampesVishit PatelSumera QureshiAndrew P CopeKatherine JonesJames B GallowayPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
This meta-analysis of RCT data defines the VTE risk with JAK inhibitors as a class in IMID patients. The pooled IRRs do not provide evidence that support the current warnings of VTE risk for JAK inhibitors. These findings will aid continued development of clinical guidelines for the use of JAK inhibitors in IMIDs.